INmune Bio (INMB) Stock Price, Quote, News & History

INmune Bio Inc (INMB) Stock Price, Quote, News & History

INMBNASDAQ

Trade with Public

$1.12

-0.08-6.67%

At close: Mar 27, 5:00 PM EST

$1.15

0.032.68%

After Hours: 6:01 PM EST

Earnings: Q4 2025 Earnings in 3 days from now on Mon Mar 30th, after the market close

Conference Call: Conference call scheduled in 3 days at 4:30 PM

Click to view the webcast

Key Statistics

Open

$1.20

$1.12

Volume / Avg.

375.67K / 435.41K

Day Range

$1.12 - $1.20

52 Wk Range

1.15 - 11.64

Market Cap

$30.57M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

16.03%

Days to Cover

5.81

Recent INmune Bio Inc News

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Mohd Haider

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Vishaal Sanjay

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Vishaal Sanjay

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-30.65M

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

25.47M

Free Cash Flow (TTM)

-31.55M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-6.08M

Analyst Trends and Forecast

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.25M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

568.03

PB Ratio (TTM)

1.26

Earnings Yield % (TTM)

-173.33%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.95

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$2.50M

Total Cash

$27.73M

Debt to Equity

0.04

Issuance of Debt (TTM)

-$2.50M

Repayment of Debt (TTM)

-$2.50M

Key Statistics

Open

$1.20

$1.12

Volume / Avg.

375.67K / 435.41K

Day Range

$1.12 - $1.20

52 Wk Range

1.15 - 11.64

Market Cap

$30.57M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

16.03%

Days to Cover

5.81

About

Sector

Health Care

Industry

Biotechnology

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune,...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy INmune Bio (INMB) stock?

You can purchase shares of INmune Bio (NASDAQ:INMB) through any online brokerage.

View our list of the best stock brokerages

Who are INmune Bio (INMB) competitors?

Other companies in INmune Bio’s space includes: Serina Therapeutics Inc (AMEX:SER), Kyntra Bio Inc (NASDAQ:KYNB), Evaxion AS (NASDAQ:EVAX), Palatin Technologies Inc (AMEX:PTN) and Sensei Biotherapeutics Inc (NASDAQ:SNSE).

What is the forecast, or price target, for INmune Bio (INMB) stock?

INmune Bio has a consensus price target of $10.80.

What is the current price for INmune Bio (INMB)?

The stock price for INmune Bio (NASDAQ: INMB) is $1.15 last updated March 27, 2026 at 6:01 PM EDT.

Does INmune Bio (INMB) pay a dividend?

There are no upcoming dividends for INmune Bio.

When is INmune Bio (NASDAQ:INMB) reporting earnings?

INmune Bio does not have any upcoming earnings scheduled.

Is INmune Bio (INMB) going to split?

There is no upcoming split for INmune Bio.

What sector and industry does INmune Bio (INMB) operate in?

INmune Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Serina Therapeutics Inc

Palatin Technologies Inc

AMEX:PTN

$19.99

-3.20%

Sensei Biotherapeutics Inc

BriaCell Therapeutics Corp

NASDAQ:BCTX

$3.86

2.93%

Key Statistics

Open

$1.20

$1.12

Volume / Avg.

375.67K / 435.41K

Day Range

$1.12 - $1.20

52 Wk Range

1.15 - 11.64

Market Cap

$30.57M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

16.03%

Days to Cover

5.81

Recent INmune Bio Inc News

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Mohd Haider

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Vishaal Sanjay

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Vishaal Sanjay

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-30.65M

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

25.47M

Free Cash Flow (TTM)

-31.55M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-6.08M

Analyst Trends and Forecast

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.25M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

568.03

PB Ratio (TTM)

1.26

Earnings Yield % (TTM)

-173.33%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.95

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$2.50M

Total Cash

$27.73M

Debt to Equity

0.04

Issuance of Debt (TTM)

-$2.50M

Repayment of Debt (TTM)

-$2.50M

Key Statistics

Open

$1.20

$1.12

Volume / Avg.

375.67K / 435.41K

Day Range

$1.12 - $1.20

52 Wk Range

1.15 - 11.64

Market Cap

$30.57M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

16.03%

Days to Cover

5.81

About

Sector

Health Care

Industry

Biotechnology

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry